Repligen (RGEN) Stock Forecast, Price Target & Predictions
RGEN Stock Forecast
Repligen stock forecast is as follows: an average price target of $189.50 (represents a 35.37% upside from RGEN’s last price of $139.99) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
RGEN Price Target
The average price target for Repligen (RGEN) is $189.50 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $207.00 to $155.00. This represents a potential 35.37% upside from RGEN's last price of $139.99.
RGEN Analyst Ratings
According to 10 Wall Street analysts, Repligen's rating consensus is 'Buy'. The analyst rating breakdown for RGEN stock is 0 'Strong Buy' (0.00%), 8 'Buy' (80.00%), 1 'Hold' (10.00%), 1 'Sell' (10.00%), and 0 'Strong Sell' (0.00%).
Repligen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Elizabeth Garcia | UBS | $185.00 | $167.35 | 10.55% | 32.15% |
| Jul 31, 2024 | Rachel Vatnsdal | J.P. Morgan | $200.00 | $167.35 | 19.51% | 42.87% |
| Jun 26, 2024 | Justin Bowers | Deutsche Bank | $155.00 | $127.00 | 22.05% | 10.72% |
| Jun 21, 2024 | Daniel Arias | Stifel Nicolaus | $207.00 | $123.16 | 68.07% | 47.87% |
| Jan 06, 2023 | - | Leerink Partners | $200.00 | $153.32 | 30.45% | 42.87% |
| Dec 14, 2022 | - | Deutsche Bank | $180.00 | $177.99 | 1.13% | 28.58% |
| Dec 07, 2022 | - | RBC Capital | $190.00 | $169.13 | 12.34% | 35.72% |
| Apr 28, 2022 | - | Leerink Partners | $220.00 | $157.51 | 39.67% | 57.15% |
The latest Repligen stock forecast, released on Jul 31, 2024 by Elizabeth Garcia from UBS, set a price target of $185.00, which represents a 10.55% increase from the stock price at the time of the forecast ($167.35), and a 32.15% increase from RGEN last price ($139.99).
Repligen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 4 |
| Avg Price Target | - | $186.75 | $186.75 |
| Last Closing Price | $139.99 | $139.99 | $139.99 |
| Upside/Downside | -100.00% | 33.40% | 33.40% |
In the current month, the average price target of Repligen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Repligen's last price of $139.99. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Wells Fargo | - | Overweight | Initialise |
| Jul 31, 2024 | UBS | Buy | Buy | Hold |
| Jun 26, 2024 | BMO Capital | - | Outperform | Upgrade |
| Jun 26, 2024 | Deutsche Bank | Hold | Buy | Upgrade |
| Jun 18, 2024 | Guggenheim | - | Neutral | Initialise |
| Feb 21, 2024 | William Blair | Outperform | Outperform | Hold |
| Oct 31, 2023 | William Blair | Outperform | Outperform | Hold |
| Jul 06, 2023 | Raymond James | - | Outperform | Initialise |
| Jul 06, 2023 | RBC Capital | Sector Perform | Outperform | Upgrade |
| Jul 06, 2023 | Piper Sandler | - | Underweight | Downgrade |
Repligen's last stock rating was published by Wells Fargo on Aug 27, 2024. The company Initialise its RGEN rating from "null" to "Overweight".
Repligen Financial Forecast
Repligen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $141.19M | $159.17M | $182.66M | $186.76M | $200.74M | $207.63M | $206.40M | $186.52M | $178.22M | $162.96M | $142.84M | $108.65M | $94.06M | $87.46M | $76.09M | $69.47M | $69.44M |
| Avg Forecast | $202.33M | $192.90M | $193.21M | $182.89M | $190.72M | $171.82M | $173.91M | $167.29M | $167.96M | $153.33M | $154.11M | $150.06M | $155.38M | $140.69M | $165.93M | $181.42M | $184.55M | $191.50M | $189.06M | $185.48M | $179.27M | $163.91M | $144.24M | $117.02M | $93.94M | $86.45M | $78.38M | $71.64M | $68.37M | $66.10M |
| High Forecast | $207.60M | $197.93M | $198.24M | $187.65M | $195.69M | $176.29M | $178.44M | $171.65M | $172.34M | $160.50M | $158.13M | $153.97M | $157.82M | $149.04M | $170.26M | $186.15M | $189.36M | $196.49M | $195.96M | $192.24M | $185.80M | $169.89M | $149.50M | $121.29M | $97.36M | $89.60M | $81.24M | $74.25M | $70.86M | $68.51M |
| Low Forecast | $199.70M | $190.40M | $190.70M | $180.52M | $188.25M | $169.59M | $171.65M | $165.12M | $165.78M | $151.61M | $152.12M | $148.12M | $151.54M | $134.19M | $163.78M | $179.07M | $182.16M | $189.01M | $186.79M | $183.24M | $177.11M | $161.94M | $142.50M | $115.61M | $92.81M | $85.40M | $77.44M | $70.78M | $67.54M | $65.31M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.96% | 1.01% | 1.01% | 1.05% | 1.10% | 1.11% | 1.04% | 1.09% | 1.13% | 1.22% | 1.16% | 1.09% | 1.12% | 1.06% | 1.02% | 1.05% |
Repligen's average Quarter revenue forecast for Dec 23 based on 7 analysts is $155.38M, with a low forecast of $151.54M, and a high forecast of $157.82M. RGEN's average Quarter revenue forecast represents a 10.05% increase compared to the company's last Quarter revenue of $141.19M (Sep 23).
Repligen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.81M | $19.40M | $32.11M | $32.12M | $55.98M | $64.53M | $68.57M | $49.11M | $54.46M | $56.48M | $44.66M | $25.36M | $27.51M | $25.50M | $20.04M | $13.39M | $10.27M |
| Avg Forecast | $41.07M | $39.15M | $39.21M | $37.12M | $38.71M | $34.87M | $35.30M | $33.95M | $34.09M | $31.12M | $31.28M | $71.41M | $31.54M | $28.55M | $33.68M | $64.92M | $37.46M | $46.80M | $38.37M | $51.32M | $36.39M | $33.27M | $29.28M | $18.71M | $19.07M | $17.55M | $15.91M | $10.50M | $13.88M | $13.42M |
| High Forecast | $42.14M | $40.17M | $40.24M | $38.09M | $39.72M | $35.78M | $36.22M | $34.84M | $34.98M | $32.58M | $32.10M | $85.69M | $32.03M | $30.25M | $34.56M | $77.90M | $38.43M | $56.16M | $39.77M | $61.58M | $37.71M | $34.48M | $30.34M | $22.46M | $19.76M | $18.19M | $16.49M | $12.60M | $14.38M | $13.91M |
| Low Forecast | $40.53M | $38.65M | $38.71M | $36.64M | $38.21M | $34.42M | $34.84M | $33.51M | $33.65M | $30.77M | $30.87M | $57.13M | $30.76M | $27.24M | $33.24M | $51.93M | $36.97M | $37.44M | $37.91M | $41.06M | $35.95M | $32.87M | $28.92M | $14.97M | $18.84M | $17.33M | $15.72M | $8.40M | $13.71M | $13.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.17% | 0.58% | 0.49% | 0.86% | 1.20% | 1.68% | 1.34% | 1.35% | 1.64% | 1.93% | 2.39% | 1.33% | 1.57% | 1.60% | 1.91% | 0.96% | 0.77% |
7 analysts predict RGEN's average Quarter EBITDA for Dec 23 to be $31.54M, with a high of $32.03M and a low of $30.76M. This is 555.94% upper than Repligen's previous annual EBITDA (Sep 23) of $4.81M.
Repligen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $18.17M | $20.06M | $28.83M | $48.73M | $40.41M | $49.86M | $46.96M | $29.11M | $33.50M | $36.23M | $29.45M | $19.70M | $14.55M | $15.86M | $9.81M | $3.60M | $1.66M |
| Avg Forecast | $37.15M | $34.25M | $34.07M | $29.49M | $31.85M | $25.87M | $25.97M | $23.31M | $27.45M | $18.86M | $18.40M | $47.20M | $18.39M | $9.30M | $26.81M | $42.91M | $32.54M | $28.79M | $40.28M | $33.92M | $36.61M | $35.94M | $29.56M | $12.34M | $17.28M | $15.59M | $15.67M | $5.14M | $10.41M | $10.86M |
| High Forecast | $38.41M | $35.41M | $35.22M | $30.49M | $32.93M | $26.75M | $26.85M | $24.10M | $28.38M | $20.01M | $19.03M | $56.64M | $19.50M | $17.45M | $27.72M | $51.49M | $33.64M | $34.54M | $42.19M | $40.70M | $38.35M | $37.64M | $30.96M | $14.81M | $18.10M | $16.33M | $16.41M | $6.17M | $10.90M | $11.38M |
| Low Forecast | $36.53M | $33.68M | $33.50M | $29.00M | $31.31M | $25.44M | $25.53M | $22.92M | $26.99M | $16.58M | $18.09M | $37.76M | $17.27M | $5.23M | $26.36M | $34.33M | $31.99M | $23.03M | $39.65M | $27.13M | $36.04M | $35.38M | $29.09M | $9.87M | $17.01M | $15.34M | $15.42M | $4.11M | $10.25M | $10.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.95% | 0.75% | 0.67% | 1.50% | 1.40% | 1.24% | 1.38% | 0.80% | 0.93% | 1.23% | 2.39% | 1.14% | 0.93% | 1.01% | 1.91% | 0.35% | 0.15% |
Repligen's average Quarter net income forecast for Dec 23 is $18.39M, with a range of $17.27M to $19.50M. RGEN's average Quarter net income forecast represents a 1.18% increase compared to the company's last Quarter net income of $18.17M (Sep 23).
Repligen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.47M | $48.97M | $56.17M | $53.24M | $53.64M | $54.65M | $54.30M | $52.06M | $48.37M | $44.34M | $39.09M | $36.34M | $29.05M | $26.73M | $27.50M | $28.29M | $24.63M |
| Avg Forecast | $60.82M | $57.99M | $58.08M | $54.98M | $57.33M | $51.65M | $52.28M | $50.29M | $50.49M | $46.09M | $46.33M | $54.57M | $46.71M | $42.29M | $49.88M | $49.61M | $55.48M | $41.57M | $56.84M | $39.22M | $53.89M | $49.27M | $43.36M | $16.38M | $28.24M | $25.99M | $23.56M | $14.40M | $20.55M | $19.87M |
| High Forecast | $62.41M | $59.50M | $59.59M | $56.41M | $58.83M | $53.00M | $53.64M | $51.60M | $51.81M | $48.25M | $47.54M | $65.48M | $47.44M | $44.80M | $51.18M | $59.53M | $56.92M | $49.88M | $58.91M | $47.06M | $55.86M | $51.07M | $44.94M | $19.66M | $29.27M | $26.93M | $24.42M | $17.29M | $21.30M | $20.60M |
| Low Forecast | $60.03M | $57.24M | $57.33M | $54.27M | $56.59M | $50.98M | $51.60M | $49.64M | $49.84M | $45.58M | $45.73M | $43.66M | $45.56M | $40.34M | $49.24M | $39.69M | $54.76M | $33.26M | $56.15M | $31.37M | $53.24M | $48.68M | $42.84M | $13.11M | $27.90M | $25.67M | $23.28M | $11.52M | $20.30M | $19.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.31% | 0.98% | 1.13% | 0.96% | 1.29% | 0.96% | 1.38% | 0.97% | 0.98% | 1.02% | 2.39% | 1.29% | 1.12% | 1.13% | 1.91% | 1.38% | 1.24% |
Repligen's average Quarter SG&A projection for Dec 23 is $46.71M, based on 7 Wall Street analysts, with a range of $45.56M to $47.44M. The forecast indicates a -15.79% fall compared to RGEN last annual SG&A of $55.47M (Sep 23).
Repligen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.33 | $0.36 | $0.52 | $0.88 | $0.73 | $0.90 | $0.85 | $0.53 | $0.61 | $0.66 | $0.54 | $0.37 | $0.28 | $0.30 | $0.19 | $0.07 | $0.03 |
| Avg Forecast | $0.66 | $0.61 | $0.60 | $0.52 | $0.56 | $0.46 | $0.46 | $0.41 | $0.49 | $0.33 | $0.33 | $0.30 | $0.33 | $0.16 | $0.48 | $0.59 | $0.58 | $0.68 | $0.71 | $0.72 | $0.65 | $0.64 | $0.52 | $0.42 | $0.31 | $0.28 | $0.28 | $0.22 | $0.18 | $0.19 |
| High Forecast | $0.68 | $0.63 | $0.62 | $0.54 | $0.58 | $0.47 | $0.48 | $0.43 | $0.50 | $0.35 | $0.34 | $0.31 | $0.35 | $0.31 | $0.49 | $0.61 | $0.60 | $0.70 | $0.75 | $0.75 | $0.68 | $0.67 | $0.55 | $0.44 | $0.32 | $0.29 | $0.29 | $0.23 | $0.19 | $0.20 |
| Low Forecast | $0.65 | $0.60 | $0.59 | $0.51 | $0.55 | $0.45 | $0.45 | $0.41 | $0.48 | $0.29 | $0.32 | $0.30 | $0.31 | $0.09 | $0.47 | $0.58 | $0.57 | $0.67 | $0.70 | $0.71 | $0.64 | $0.63 | $0.52 | $0.42 | $0.30 | $0.27 | $0.27 | $0.22 | $0.18 | $0.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.00% | 0.76% | 0.88% | 1.53% | 1.07% | 1.26% | 1.18% | 0.82% | 0.96% | 1.26% | 1.28% | 1.21% | 1.01% | 1.08% | 0.86% | 0.38% | 0.16% |
According to 7 Wall Street analysts, Repligen's projected average Quarter EPS for Dec 23 is $0.33, with a low estimate of $0.31 and a high estimate of $0.35. This represents a -1.28% decrease compared to RGEN previous annual EPS of $0.33 (Sep 23).
Repligen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| ANGO | AngioDynamics | $7.64 | $17.00 | 122.51% | Buy |
| HAE | Haemonetics | $76.09 | $104.33 | 37.11% | Buy |
| RGEN | Repligen | $139.99 | $189.50 | 35.37% | Buy |
| TFX | Teleflex | $246.05 | $304.09 | 23.59% | Buy |
| NVST | Envista | $19.41 | $23.83 | 22.77% | Hold |
| BDX | Becton, Dickinson and Company | $234.18 | $280.55 | 19.80% | Buy |
| WST | West Pharmaceutical Services | $300.67 | $345.33 | 14.85% | Buy |
| HOLX | Hologic | $81.15 | $78.92 | -2.75% | Buy |
| MMSI | Merit Medical Systems | $96.16 | $93.38 | -2.89% | Buy |
| RMD | ResMed | $248.93 | $209.33 | -15.91% | Hold |
| ISRG | Intuitive Surgical | $489.86 | $393.85 | -19.60% | Buy |
| ICUI | ICU Medical | $179.00 | $135.00 | -24.58% | Buy |
| ATR | AptarGroup | $152.28 | $100.00 | -34.33% | Buy |
RGEN Forecast FAQ
Is Repligen a good buy?
Yes, according to 10 Wall Street analysts, Repligen (RGEN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 80.00% of RGEN's total ratings.
What is RGEN's price target?
Repligen (RGEN) average price target is $189.5 with a range of $155 to $207, implying a 35.37% from its last price of $139.99. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Repligen stock go up soon?
According to Wall Street analysts' prediction for RGEN stock, the company can go up by 35.37% (from the last price of $139.99 to the average price target of $189.5), up by 47.87% based on the highest stock price target, and up by 10.72% based on the lowest stock price target.
Can Repligen stock reach $200?
RGEN's highest twelve months analyst stock price target of $207 supports the claim that Repligen can reach $200 in the near future.
What are Repligen's analysts' financial forecasts?
Repligen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $703.73M (high $722.06M, low $694.6M), average EBITDA is $142.83M (high $146.56M, low $140.98M), average net income is $107M (high $110.63M, low $105.2M), average SG&A $211.55M (high $217.06M, low $208.81M), and average EPS is $1.9 (high $1.96, low $1.86). RGEN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $771.32M (high $791.42M, low $761.32M), average EBITDA is $156.55M (high $160.63M, low $154.52M), average net income is $134.97M (high $139.54M, low $132.69M), average SG&A $231.87M (high $237.91M, low $228.86M), and average EPS is $2.39 (high $2.47, low $2.35).
Did the RGEN's actual financial results beat the analysts' financial forecasts?
Based on Repligen's last annual report (Dec 2022), the company's revenue was $801.54M, beating the average analysts forecast of $750.59M by 6.79%. Apple's EBITDA was $184.6M, beating the average prediction of $173.95M by 6.12%. The company's net income was $185.96M, beating the average estimation of $135.53M by 37.21%. Apple's SG&A was $215.83M, beating the average forecast of $193.1M by 11.77%. Lastly, the company's EPS was $3.35, beating the average prediction of $2.69 by 24.52%. In terms of the last quarterly report (Sep 2023), Repligen's revenue was $141.19M, beating the average analysts' forecast of $140.69M by 0.36%. The company's EBITDA was $4.81M, missing the average prediction of $28.55M by -83.16%. Repligen's net income was $18.17M, beating the average estimation of $9.3M by 95.31%. The company's SG&A was $55.46M, beating the average forecast of $42.29M by 31.15%. Lastly, the company's EPS was $0.33, beating the average prediction of $0.165 by 100.16%